GLP1R and metabolic dysfunction-associated steatotic liver disease: First, the glitazones and newer therapies for T2D including the glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium–glucose co-transporter-2 inhibitors (SGLT2i) have evidence of benefit in NAFLD/NASH [29].